Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword

BioDrugs. 2010 Dec 14:24 Suppl 1:1-2. doi: 10.2165/11586300-000000000-00000.

Author

Fernando Magro¹

Affiliation

¹ Portuguese Group of Studies of Inflammatory Bowel Diseases, Gastroenterology Department of Hospital de São João, Institute of Pharmacology and Therapeutics-Faculty of Medicine, Oporto University, Portugal.

PMID: 21175227
DOI: 10.2165/11586300-000000000-00000

No abstract available

Publication types

Introductory Journal Article

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Crohn Disease / drug therapy*
Crohn Disease / surgery
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / surgery
Infliximab
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Tumor Necrosis Factor-alpha
Infliximab